Table 3.

Responses observed in patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma (B‐NHL) after treatment with salvage chemoimmunotherapy incorporating cyclophosphamide, cytarabine, etoposide, dexamethasone, and rituximab

Type of B‐NHL	Prior treatment	Total no.	CR or Cru	Overall response
Indolent B‐NHL	All	n = 17	n = 16	n = 17
			94% (71–99%)	100% (84–100%)
	Previous rituximab	n = 12	n = 11	n = 12
			92% (62–99%)	100% (78–100%)
	Rituximab‐naive	n = 5	n = 5	n = 5
			100% (55–100%)	100% (55–100%)
Aggressive B‐NHL	All	n = 15	n = 8	n = 10
			53% (27–79%)	67% (38–88%)
	Previous rituximab	n = 8	n = 4	n = 5
			50% (16–84%)	63% (24–91%)
	Rituximab‐naive	n = 7	n = 4	n = 5
			57% (18–90%)	71% (29–96%)
Total	All	n = 32	n = 24	n = 27
			75% (57–89%)	84% (67–95%)
	Previous rituximab	n = 20	n = 15	n = 17
			75% (51–91%)	85% (62–97%)
	Rituximab‐naive	n = 12	n = 9	n = 10
			75% (43–95%)	83% (52–98%)

Ranges in parentheses indicate 95% confidence interval. CR, complete response; CRu, complete response unconfirmed.